Company News

Procter & Gamble Granted Cell Research License from Geron

Author Image

By: TOM BRANNA

Editor

Biopharmaceutical company Geron Corp., Menlo Park, CA, has granted a non-exclusive license to Procter & Gamble Company for Geron’s human telomerase reverse transcriptase technology in cell research applications. Financial terms of the agreement were not disclosed.

The technology will allow Procter & Gamble to conduct repeated or long-term studies on the biology and function of cells using hTERT technology, which proliferate indefinitely while maintaining normal physical and biological characteristics, according to reports.

Keep Up With Our Content. Subscribe To Happi Newsletters